<DOC>
	<DOCNO>NCT00273312</DOCNO>
	<brief_summary>This study evaluate safety , efficacy , activity patupilone patient advance unresectable and/or metastatic hepatocellular carcinoma base tumor response use modify RECIST criterion .</brief_summary>
	<brief_title>Patupilone Activity Advanced/Metastatic Hepatocellular Carcinoma</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Hepatocellular</mesh_term>
	<mesh_term>Epothilone B</mesh_term>
	<mesh_term>Epothilones</mesh_term>
	<criteria>Inclusion criterion : Hepatocellular carcinoma patient least 1 previously unirradiated , measurable lesion without systemic single agent combination chemotherapy . Previous local therapy allow . Exclusion criterion : Additional protocoldefined inclusion/exclusion criterion apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Advanced unresectable metastatic hepatocellular carcinoma</keyword>
	<keyword>Liver cancer</keyword>
</DOC>